爱博医疗：拟收购德美医疗不低于51%的股权并取得其控制权

Group 1 - The company plans to acquire at least 51% of the equity of Demai Medical, with an estimated overall valuation not exceeding RMB 1 billion [1] - The preliminary transaction price is based on a comprehensive assessment of the target company's technological advancement, business development, and past operating performance, while also considering industry valuation levels and business synergy [1] - The final transaction price will be determined based on an evaluation report from a qualified asset appraisal agency and negotiations among the parties involved [1] Group 2 - The target company is a leading enterprise in sports medicine in China, recognized as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small giant, holding 276 patent technologies [2] - The target company has established a modern production base and R&D center, demonstrating strong technological research and market competitiveness, and is included in the fourth batch of national high-value medical consumables procurement A group [2] - The acquisition will enhance the company's layout in the medical health sector, leveraging synergies in R&D, manufacturing, and sales channels to further improve performance and shareholder returns [2]